Process Ready Automation for Critical Bioprocess Operations

Meissner’s automation solutions help biopharmaceutical manufacturers reduce operator variability, improve repeatability, and simplify execution across critical single-use workflows, including the pre-use post-sterilization integrity testing (PUPSIT) and aliquoting operations at the center of today’s EU GMP Annex 1 contamination control expectations.

Automation built around risk reduction

In critical processing environments, manual steps can introduce variability, increase training dependence, and create avoidable operational burden. This is exactly where regulators have turned their attention: the revised EU GMP Annex 1 specifically identifies robotics and automation as ways to eliminate direct human intervention in critical process steps. Meissner approaches automation as a practical way to provide error-proofing, remove sources of variability, and improve operational efficiency where process control, and regulatory scrutiny, matter most.

Focused automation for high-value process steps

Meissner’s automation portfolio is designed around specific workflow needs rather than a broad digital-platform story. That means no software licensing tiers to navigate, no proprietary ecosystem to commit to, and no multi-system rollout to coordinate before a single process step is standardized. It gives clients a more focused path to atomization and standardizing critical operations, combined with digitalization and nonfalsifiable data. Data integrity, traceability, audit readiness by design, not by documentation alone. such as aliquoting and filtration.

Two Platforms. One Workflow Strategy.

Automated Aliquoting
System AAS

Learn More

Standardize critical aliquoting workflows with automation designed to improve consistency, simplify operator interaction, and reduce dependence on manual technique, supporting the same contamination control and minimal-intervention principles EU GMP Annex 1 applies across every Grade A operation.

Automated Filtration
System AFS

Learn More

Bring greater control and repeatability to critical filtration workflows, including pre-use post-sterilization integrity testing (PUPSIT), with automation designed to simplify execution and support Annex 1’s expectations for closed-system, in-place integrity testing in single-use bioprocess environments.

Why Meissner?

• • Automation designed to reduce risk and remove workflow variability, addressing the same operator-driven risks EU GMP Annex 1 identifies as sources of contamination.
• • Built around Annex 1’s expectations for pre-use post-sterilization integrity testing (PUPSIT) and closed-system filter integrity testing.
• • Strong fit with Meissner’s filtration and single-use systems expertise.
• • Engineering-led support rooted in process understanding and operational execution.
• • A specialist approach for critical operations rather than platform sprawl: no licensing tiers, no ecosystem lock-in.

Built to fit within the broader Meissner portfolio

Automation extends the value of Meissner’s broader portfolio by helping customers move from high-performing components and assemblies to more standardized workflow execution. Within Meissner’s single-use systems, our fluid path assemblies, bioprocessing containers, tubing, and connectivity solutions are already positioned to reduce process risk and optimize fluid handling, creating a natural foundation for automation-led workflow control.

Meissner ‒ Partnership to Automation

At Meissner, we deliver an integrated offering across bioprocessing unit operations and single‑use technologies empowering clients with a holistic solution to reduce risk, enhance compliance, and increase efficiency through automation.

Our engineering teams can assist in review of automation project requirements to help ensure optimized design and implementation, from capital equipment through single-use assemblies.

Let’s talk single-use automation. Send a message to our industry experts.